Evidence map›Paper›PMID 38561467›Full record

ArticleMolecular psychiatry2024

Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT

Supriya A Gaitonde, Charlotte Avet, Mario de la Fuente Revenga, Elodie Blondel-Tepaz, Aida Shahraki, Adrian Morales Pastor, Valerij Talagayev, Patricia Robledo, Peter Kolb, Jana Selent and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
18.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. The structure of the dopamine DScience advances · 2026
    Article
  4. Review
  5. Trip killers: Addressing a critical knowledge gap in psychedelic research.Journal of psychopharmacology (Oxford, England) · 2026
    Review
  6. Antidepressant Augmentation of Antipsychotic Treatment in Schizophrenia: A Narrative Review.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  7. Article
  8. Distinct structural deficits in treatment-resistant schizophrenia and their putative neurotransmitter basis: a source-based morphometry analysis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  9. Article
  10. Biased signalingActa pharmaceutica Sinica. B · 2025
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 4 countries.

Supriya A GaitondeInstitute for Research in Immunology and Cancer (IRIC), Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, H3T 1J4, Canada.
Charlotte AvetInstitute for Research in Immunology and Cancer (IRIC), Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, H3T 1J4, Canada.
Mario de la Fuente RevengaDepartment of Physiology and Biophysics, School of Medicine, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Elodie Blondel-TepazInstitute for Research in Immunology and Cancer (IRIC), Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, H3T 1J4, Canada.
Aida ShahrakiDepartment of Pharmaceutical Chemistry, Philipps-Universität Marburg, Marbacher Weg 8, 35032, Marburg, Germany.
Adrian Morales PastorResearch Programme on Biomedical Informatics (GRIB), IMIM-Hospital del Mar Medical Research Institute, Barcelona, 08003, Spain.
Valerij TalagayevDepartment of Pharmaceutical Chemistry, Philipps-Universität Marburg, Marbacher Weg 8, 35032, Marburg, Germany.ORCID 0000-0002-1907-9594
Patricia RobledoIntegrative Pharmacology and Systems Neuroscience Research Group, IMIM-Hospital del Mar Medical Research Institute, Barcelona, 08003, Spain.ORCID 0000-0002-7941-0939
Peter KolbDepartment of Pharmaceutical Chemistry, Philipps-Universität Marburg, Marbacher Weg 8, 35032, Marburg, Germany.ORCID 0000-0003-4089-614X
Jana SelentResearch Programme on Biomedical Informatics (GRIB), IMIM-Hospital del Mar Medical Research Institute, Barcelona, 08003, Spain.
Javier González-MaesoDepartment of Physiology and Biophysics, School of Medicine, Virginia Commonwealth University, Richmond, VA, 23298, USA.ORCID 0000-0003-3105-3204
Michel BouvierInstitute for Research in Immunology and Cancer (IRIC), Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, H3T 1J4, Canada. michel.bouvier@umontreal.ca.ORCID 0000-0003-1128-0100
Institute for Research in Immunology and Cancer · CAHospital Del Mar · ESPhilipps University of Marburg · DEVirginia Commonwealth University · US

Funding

Structure and function of the 5HT2A/mGluR2 complex in schizophreniaR01MH084894 · NIMH · VIRGINIA COMMONWEALTH UNIVERSITY · PI Javier Gonzalez-Maeso · 2009 to 2026
$6.8M
NIMH NIH HHS R01 MH084894
6 · The paper itself

Abstract

The intricate involvement of the serotonin 5-HT

Indexed as

Antipsychotic AgentsReceptor, Serotonin, 5-HT2ASchizophreniaSignal TransductionAripiprazoleClozapineHaloperidolHEK293 CellsHumansOlanzapineRisperidoneSerotoninSerotonin 5-HT2 Receptor AgonistsAntipsychotic AgentsAripiprazoleClozapineHaloperidolOlanzapineReceptor, Serotonin, 5-HT2ARisperidoneSerotoninSerotonin 5-HT2 Receptor Agonists

Identifiers

PMID38561467
PMCPMC11420065
OpenAlexW4393443897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.